Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NYSE]
Sanofi
Index- P/E22.04 EPS (ttm)2.21 Insider Own16.40% Shs Outstand2.55B Perf Week-0.21%
Market Cap124.01B Forward P/E13.92 EPS next Y3.49 Insider Trans0.00% Shs Float2.22B Perf Month1.16%
Income5.66B PEG2.86 EPS next Q0.97 Inst Own10.10% Short Float0.10% Perf Quarter0.14%
Sales43.26B P/S2.87 EPS this Y1.40% Inst Trans-6.90% Short Ratio1.77 Perf Half Y9.28%
Book/sh27.25 P/B1.78 EPS next Y4.67% ROA- Target Price55.00 Perf Year26.57%
Cash/sh- P/C- EPS next 5Y7.70% ROE- 52W Range36.81 - 50.24 Perf YTD20.28%
Dividend1.64 P/FCF- EPS past 5Y-4.60% ROI6.20% 52W High-2.13% Beta0.85
Dividend %3.37% Quick Ratio1.20 Sales past 5Y-0.20% Gross Margin68.60% 52W Low33.58% ATR0.52
Employees106859 Current Ratio1.60 Sales Q/Q9.80% Oper. Margin- RSI (14)57.03 Volatility0.88% 0.81%
OptionableYes Debt/Eq0.32 EPS Q/Q20.70% Profit Margin- Rel Volume0.76 Prev Close48.64
ShortableYes LT Debt/Eq0.26 EarningsJul 31 BMO Payout- Avg Volume1.24M Price49.17
Recom1.70 SMA200.84% SMA501.98% SMA2008.32% Volume216,833 Change1.09%
Aug-30-17Upgrade HSBC Securities Reduce → Hold
May-11-17Downgrade Berenberg Buy → Hold
Apr-07-17Downgrade HSBC Securities Hold → Reduce
Apr-06-17Initiated Argus Buy $50
Mar-09-17Initiated Liberum Hold
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Sep-18-17 07:30PM  5 Top Marijuana Stocks For 2017 Oilprice.com
05:06PM  Could Mylan See a Rise in Net Profit Margins in 2017? Market Realist
07:37AM  Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017 Market Realist
Sep-16-17 02:17AM  Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis GlobeNewswire
02:15AM  Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis PR Newswire
Sep-15-17 10:38AM  Label Expansion in Asthma Indication May Boost Dupixents Sales Market Realist
09:10AM  Regulatory Approval in Asthma Indication May Boost Dupixents Sales Market Realist
07:38AM  Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis Market Realist
Sep-14-17 12:32PM  Why Lexicon Pharmaceuticals Is Down 11% Today Motley Fool
07:00AM  Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice PR Newswire
Sep-12-17 01:26PM  Sanofi indicates dupilumab could be used to treat nasal polyps Reuters
07:01AM  Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL PR Newswire
06:48AM  5 Things Regeneron's CEO Said as the Biotech Stock Sank Motley Fool
Sep-11-17 02:15PM  Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints Zacks
01:08PM  Regeneron, Sanofi asthma drug data fails to excite investors Reuters
07:25AM  Featured Company News - Regeneron Pharma and Sanofi's Cemiplimab Receives Breakthrough Therapy Designation from US FDA ACCESSWIRE
01:14AM  Sanofi and Regeneron announce positive dupilumab topline results Reuters
01:00AM  Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma PR Newswire
Sep-08-17 05:42PM  Regeneron's Cemiplimab Gains Breakthrough Therapy Status Zacks
02:59AM  Sanofi says Cemiplimab skin cancer treatment gets FDA "Breakthrough Designation" Reuters
01:00AM  Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
Sep-07-17 10:52AM  Why Regeneron Is Getting Smoked Barrons.com
09:49AM  [$$] Sanofi Stops Work on Two Zika Vaccines The Wall Street Journal
08:50AM  Sanofi Has Good Potential Upside TheStreet.com
Sep-04-17 09:51AM  Why Is Regeneron (REGN) Up 7.9% Since the Last Earnings Report? Zacks
Sep-01-17 09:54AM  The Pullback In Sanofi Is A Buying Opportunity, Says Argus Benzinga
Aug-30-17 07:20AM  Corporate News Blog - Sanofi Completes Acquisition of Vaccines Biotechnology Company, Protein Sciences ACCESSWIRE
Aug-29-17 08:03AM  3 Healthcare Stocks to Buy With Dividends Yielding More Than 3% Motley Fool
Aug-26-17 03:20PM  3 International Stocks for Retirees Motley Fool
Aug-25-17 09:07AM  Januvia and Janument: An Update on Mercks Diabetes Franchise after 2Q17 Market Realist
08:00AM  Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017 PR Newswire
07:37AM  How Mercks Vaccines Business Is Positioned after 2Q17 Market Realist
Aug-24-17 11:53AM  Can Sanofi (SNY) Sustain the Solid 1H Momentum in 2H17? Zacks
09:51AM  The Zacks Analyst Blog Highlights: Duke Energy, Stryker, Sanofi, PPL Corp and Viacom Zacks
Aug-23-17 03:50PM  Top Stock Reports for Duke Energy, Stryker & Sanofi Zacks
Aug-22-17 04:04PM  Top 10 Dividend-Paying Stocks Worldwide Forbes
03:20PM  What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline? Motley Fool
09:07AM  Mylan's Stock Is No Longer A Buy According To Analysts At Argus Benzinga
Aug-21-17 05:59PM  One of the 33 Great Minds of Investing GuruFocus.com
09:31AM  Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why Zacks
Aug-18-17 10:37AM  A Look at Sanofi Pasteurs Performance in 2Q17 Market Realist
09:07AM  Sanofis General Medicines and Consumer Healthcare in 2Q17 Market Realist
07:37AM  Performance of Sanofis Established Products in 2Q17 Market Realist
04:18AM  European Pharma Companies Slip on MS Pricing Probe TheStreet.com
Aug-17-17 10:36PM  Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy? Motley Fool
06:33PM  Seattle Genetics' Adcetris Granted Priority Review by FDA Zacks
05:48PM  Sen. Grassley says Mylan's $465 million Epi-Pen settlement 'shortchanges' taxpayers CNBC
04:24PM  EpiPen maker finalizes settlement for government overcharges Associated Press
12:49PM  EpiPen maker settles federal claims for $465M a year after Sanofi filed suit American City Business Journals
12:33PM  Mylan Finalizes $465 Million EpiPen Settlement With DoJ TheStreet.com
10:49AM  Mylan, U.S. finalize $465 million EpiPen settlement Reuters
10:37AM  How Sanofis Diabetes and Cardiovascular Franchise Performed Market Realist
09:07AM  Sanofi Genzyme Continues Driving Revenue Growth in 2Q17 Market Realist
07:37AM  Sanofis Revenue Growth in 2Q17 Market Realist
Aug-16-17 06:41PM  ETFs with exposure to Sanofi : August 16, 2017 Capital Cube
06:11PM  Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial Zacks
05:44PM  Spectrum (SPPI) Initiates Phase II Study for Cancer Drug Zacks
05:18PM  Shire Files Marketing Application for Lifitegrast in Europe Zacks
04:44PM  A Look at Sanofis Post-2Q17 Valuation Market Realist
Aug-15-17 09:06AM  Pfizers Important Product Developments in 2Q17 Market Realist
Aug-12-17 02:51PM  Where Does Zika Virus Vaccine Research Stand Now? Benzinga
Aug-11-17 08:42AM  Forget Teva (TEVA), Buy These 4 Drug Stocks Instead Zacks
Aug-10-17 04:17PM  Catalyst (CPRX) Posts Narrower than Expected Loss in Q2 Zacks
Aug-08-17 09:25AM  Forget Bayer, Buy These 3 Drug Stocks Instead Zacks
Aug-07-17 12:32PM  This Week's Pharma, Energy IPOs Benzinga
Aug-04-17 08:41AM  AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2 Zacks
Aug-03-17 04:43PM  Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View Zacks
04:23PM  The Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise Investor's Business Daily
04:15PM  Sanofi :SNY-US: Earnings Analysis: For the six months ended June 30, 2017 : August 3, 2017 Capital Cube
12:17PM  Regeneron: Wait, I Thought It Was Good News?!?! Barrons.com
Aug-01-17 04:15PM  Why Sanofi Earnings Spooked Regeneron Shares To A 6-Week Low Investor's Business Daily
03:08PM  Regeneron: Time to Sell? Barrons.com
12:26PM  Prince Edward Island includes LEMTRADA® (alemtuzumab) on provincial drug program for eligible patients CNW Group
10:38AM  Analysts Recommendations for Regeneron in July 2017 Market Realist
Jul-31-17 11:02PM  Sanofi meets 2Q profit forecasts Associated Press
04:11PM  Why Clovis, Regeneron Are Leading A Biotech Deluge Today Investor's Business Daily
03:05PM  Praluent Could Witness Steady Growth in 2017 Market Realist
02:46PM  Biotech Is Only Expensive When You Follow the Crowd Bloomberg
02:38PM  Sanofi: Online Availability of Sanofi Group's Half-Year Financial Report for 2017 GlobeNewswire
01:56PM  ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up Zacks
12:22PM  Story Stocks from Briefing.com Briefing.com
12:04PM  Sanofi raises outlook but key eczema drug disappoints investors Reuters
12:02PM  How Regeneron Pharmaceuticals Is Expected to Perform in 2017 Market Realist
11:11AM  [$$] Sanofi Profit Declines, Hurt by Restructuring Costs The Wall Street Journal
10:44AM  Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise Zacks
10:41AM  Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised Zacks
10:17AM  Why Regeneron is Slumping Barrons.com
09:44AM  [$$] Sanofi raises outlook after strong second-quarter sales Financial Times
07:49AM  Early movers: SNI, BA, FB, LH, COH, GPRO, SNY & more CNBC
07:40AM  Investor Network: Sanofi to Host Earnings Call ACCESSWIRE
07:32AM  Sanofi Is Selling a Ton of Vaccines So It Decided to Hike Its Profit Outlook TheStreet.com
07:30AM  Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER PR Newswire
03:30AM  Sanofi's CFO Says Growth in EM Has Been Steady Bloomberg Video
Jul-28-17 05:05PM  Why Shares of ImmunoGen Inc. Shot Up Today Motley Fool
Jul-27-17 11:37AM  Green River (City of) WY, Variable Rate Demand Revenue Bonds (Rhone-Poulenc of Wyoming, L.P. Project), Series 1994, $11.4MM -- Moody's Affirms A1/VMIG 1 on Green River, WY's LOC-backed VRDBs (Rhone-Poulenc of WY, L.P.) Series 1994 Moody's
11:07AM  Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View Zacks
Jul-26-17 11:23AM  Eli Lilly: The Competition is Just Too Darn Intense! Barrons.com
Jul-24-17 02:06PM  FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20) Reuters
07:30AM  Featured Company News - Regeneron and Sanofi Receive Positive CHMP's Opinion for Dupixent(R) Accesswire
Jul-21-17 04:43PM  Merck's Biosimilar Insulin Gets Tentative FDA Approval Zacks
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; and Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerAug 25Buy481.3672,37834,840,13323,880,537Aug 29 05:00 PM
Sanofi10% OwnerAug 24Buy482.04105,82051,009,57223,808,159Aug 25 05:00 PM
Sanofi10% OwnerAug 23Buy478.9860,59529,024,05023,702,339Aug 25 05:00 PM
Sanofi10% OwnerJun 02Buy478.17136,05065,055,55823,641,744Jun 06 05:00 PM
Sanofi10% OwnerJan 11Buy369.7187,29832,274,87223,505,694Jan 13 04:15 PM